Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — H1 2026 Earnings Presentation
18 slides from Burjeel's earnings presentation, August 2026
Slide 1: Q2 & H1 2026 Financial Results
Q2 & H1 2026 Financial Results Earnings Presentation August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in the GCC
Slide 4: H1'26: Reinforcing Resilience. Unlocking Value.
H1’26: Reinforcing Resilience. Unlocking Value. Key Highlights Reiterated Strategy: Anchoring the UAE Platform, Scaling Asset-Light Growth Across GCC & Beyond Revenue AED 2,794m UAE Expansion HealthTech +4.4% YoY Core Network Densification Enables platform 2 hospitals | 4 day surgery integration, ce
Slide 5: Recent Business Developments
Recent Business Developments 44 20 Strengthening Access to Global Capital Markets Medical Hospitals Successfully completed the inaugural USD 500 million Sukuk, Centers attracting a 3.2x oversubscribed orderbook with 61% international investor allocation and reinforcing the Group’s long-term funding
Slide 6: Recent Medical Developments
Recent Medical Developments Delivering 45,880 Total Surgeries Da Vinci Xi Advancing Transplant Medicine Burjeel Medical City achieved further milestones in its multi- 1,075 organ transplant program, completing 15 kidney and four liver Robotic Surgeries transplants in 2026 and bringing the cumulative
Slide 7: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in the GCC
Slide 8: Accelerating Patient Volume Growth with Expanding Market Presence
Accelerating Patient Volume Growth with Expanding Market Presence Group Outpatient Footfall, k Group Inpatient Footfall, k % OP utilization • Total patient volumes increased 9.9% YoY to % bed occupancy • Inpatient footfall rose 8.4% in Q2’26 and over 3.7 million in H1'26, with growth 7.2% in H1’26,
Slide 9: Delivered Strong Underlying Performance Despite Challenging Market Headwinds
Delivered Strong Underlying Performance Despite Challenging Market Headwinds Group Revenue, AED m Group EBITDA, AED m YoY • Q2’26 Group Revenue increased 3.7% YoY, EBITDA margin (ex-one-offs) YoY • Q2’26 Group EBITDA ex-one-offs2 rose while patient visits accelerated to 12.4% 35.0% YoY, with the mar
Slide 10: Margin Normalization Progressing Through Asset Maturity & Cost Discipline
Margin Normalization Progressing Through Asset Maturity & Cost Discipline Group OPEX Breakdown, % of Revenue Group EBITDA Analysis, AED m % EBITDA margin 83.4% 84.7% 81.3% 21.8% 16.7% 21.7% 20.0% 78.2% +85 8.7% 11.3% 11.3% 12.1% 3.9% 3.5% (17) +7 (41) 3.4% +53 26.8% 3.3% 25.2% 20.0% 306 (72) (4) 316
Slide 11: Strong Free Cash Flow Generation Along With Disciplined Capital Deployment
Strong Free Cash Flow Generation Along With Disciplined Capital Deployment Net Cash from Operating Activities, AED m Net Cash Used In Investing Activities, AED m % FCF conversion1 Growth CAPEX Maintenance CAPEX Net acquisitions and investments in associates 53% 72% 297 129 53 +67 +2 (8) 405 +96 +19
Slide 12: Well-Capitalized Balance Sheet Enhanced by Successful Debt Refinancing
Well-Capitalized Balance Sheet Enhanced by Successful Debt Refinancing AED m 30 June 2026 31 December 2025 Debt Maturity as of 31 July 2026 Bank balances and cash 224 277 1,837 Interest-bearing loans and borrowings 1,877 1,918 Bank overdraft — — Bank debt1 78 1,877 1,918 Net debt 1,653 1,641 2026 20
Slide 13: Mid-Term Outlook & Guidance
Mid-Term Outlook & Guidance Network Expansion Profitability 18 Healthcare Assets: 2 Hospitals — Dubai, 4 Day Surgery Centers — Group EBITDA margin expected to expand to the low-20s UAE, 6 Medical Centers — UAE, 2 Fertility Clinics — Al Ain and range on a blended basis, driven by asset ramp-up, scale
Slide 14: Q&A
Q&A Leading Super-Specialty Healthcare Provider in the GCC
Slide 15: H1'26 Income Statement
H1’26 Income Statement Group Income Statement Summary Financial Performance by Segment AED m Q2’26 Q2’25 H1’26 H1’25 AED m Q2’26 Q2’25 H1’26 H1’25 Revenue 1,455 1,403 2,794 2,677 Revenue 1,455 1,403 2,794 2,677 Inventories consumed (290) (375) (559) (674) Hospitals4 1,312 1,245 2,501 2,371 Doctors’
Slide 16: H1'26 Balance Sheet
H1’26 Balance Sheet Balance Sheet Summary AED m 30 June 2026 31 Dec 2025 AED m 30 June 2026 31 Dec 2025 Shareholders' equity Non-current assets Share capital 521 521 Property and equipment 2,081 2,133 Shareholder’s contribution 4 4 Intangible assets 17 20 Other reserves 3 3 Right-of-use assets 1,027
Slide 17: H1'26 Cash Flow Statement
H1’26 Cash Flow Statement Cash Flow Summary AED, m H1’26 H1‘25 Operating activities Net Profit for the Period Before Tax 227 208 Non-cash movements 419 323 Working capital movements (175) (242) Other (66) (60) Net Cash, Operating activities 405 229 Investing activities CAPEX (property, equipment, CW
Slide 18: IR Contacts
IR Contacts August 2026 Sergei Levitskii Director of Investor Relations Investor Feedback Hotline sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 Engaging openly with our investors and analysts is a cornerstone of our approach. We’ve partnered with Closir to make sharing your feedback quick